A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study constitutes an open‐label, multi‐cohort, multi‐center Phase Ib/II clinicalstudy, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090injection when administered in combination with bevacizumab, or in triple combinationwith bevacizumab and chemotherapy, among patients diagnosed with advanced colorectalcancer.
Epistemonikos ID: 940fa062c5c4c27790b44487252835ecc880fd53
First added on: Aug 07, 2026